# Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)

> **NCT03018288** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 90 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Pembrolizumab
- **BIOLOGICAL:** HSPPC-96
- **DRUG:** Temozolomide
- **OTHER:** Placebo
- **PROCEDURE:** Surgery

## Key facts

- **NCT ID:** NCT03018288
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-09-21
- **Primary completion:** 2022-12-20
- **Final completion:** 2022-12-20
- **Target enrollment:** 90 (ACTUAL)
- **Why stopped:** Study closed early due to poor accrual.
- **Last updated:** 2025-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03018288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03018288, "Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03018288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*